Lyra Therapeutics, Inc. - Common Stock (LYRA)

CUSIP: 55234L204

Q3 2025 13F Holders as of 30 Sep 2025

Type / Class
Equity / Common Stock
Shares outstanding
1,769,273
Total 13F shares
448,588
Share change
-45,151
Total reported value
$2,933,978
Price per share
$6.53
Number of holders
25
Value change
-$324,008
Number of buys
8
Number of sells
20

Quarterly Holders Quick Answers

What is CUSIP 55234L204?
CUSIP 55234L204 identifies LYRA - Lyra Therapeutics, Inc. - Common Stock in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of Lyra Therapeutics, Inc. - Common Stock (LYRA) as of Q3 2025

As of 30 Sep 2025, Lyra Therapeutics, Inc. - Common Stock (LYRA) was held by 25 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 448,588 shares. The largest 10 holders included PERCEPTIVE ADVISORS LLC, SABBY MANAGEMENT, LLC, VANGUARD GROUP INC, Ikarian Capital, LLC, CITADEL ADVISORS LLC, GEODE CAPITAL MANAGEMENT, LLC, UBS Group AG, BlackRock, Inc., ROYAL BANK OF CANADA, and MORGAN STANLEY. This page lists 25 institutional shareholders reporting positions in this security for the Q3 2025 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.